Compound ID | 56
Synonym(s): Cytolex TM | MSI-78 | MSI 78 | MSI78 | Locilex
Class: Antimicrobial peptide
| Agent Type: | Synthetic; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Membrane-active agent. Membrane disruption involving pore formation and membrane damage. |
| Target Pathogen: | Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecium, Enterococcus faecalis, Corynebacterium species, Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. |
| Combined with other compounds: | Yes |
| Propensity to select resistant mutants: | Low |
| Description: | Synthetic 22-amino-acid cationic antimicrobial peptide and analogue of magainin 2, developed for topical treatment of infected diabetic foot ulcers. |
| Institute where first reported: | Magainin Pharmaceuticals; JMI Laboratories, USA / Dipexium Pharmaceuticals (DPRX) |
| Year first mentioned: | 1998 |
| Highest development stage: | Phase 3 |
| Development status: | Inactive |
| Reason dropped: | Phase 3 trials failed to demonstrate superiority over vehicle/standard wound care |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/16132253 |
| Guide to Pharmacology: | pexiganan |
| Citations: |
|